Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine

Simple item page
dc.contributor.authorAbi Zeid Daou, Christophe
dc.contributor.authorNatout, Mohammad Ali
dc.contributor.authorEl Hadi, Nadine
dc.contributor.departmentOtolaryngology/Head and Neck Surgery
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:09:30Z
dc.date.available2025-01-24T12:09:30Z
dc.date.issued2021
dc.description.abstractIn the setting of a coronavirus disease 2019 (COVID-19) global pandemic and increased disease burden, vaccination has become one of the major solutions. With the increase in vaccination numbers worldwide, it is important to stay vigilant to the potential side effects and life-threatening complications of such vaccines. We report the case of a 30-year-old male with a biphasic allergic reaction post messenger (mRNA) Pfizer-BioNTech COVID-19 vaccination. Several reports of allergic reactions have been cited in the literature after the administration of the mRNA Pfizer-BioNTech COVID-19 vaccine. It is important to keep a high index of suspicion in severe anaphylactic cases as some patients may have a recurrence of symptoms after discharge. It is crucial to acknowledge the potential risk of anaphylaxis in select individuals and have the appropriate measures in place to deal with adverse events. In case of severe symptoms, the administration of epinephrine is advised to prevent the development of a delayed biphasic anaphylactic reaction. © 2021 Wiley Periodicals LLC
dc.identifier.doihttps://doi.org/10.1002/jmv.27109
dc.identifier.eid2-s2.0-85107213766
dc.identifier.pmid34050949
dc.identifier.urihttp://hdl.handle.net/10938/32077
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofJournal of Medical Virology
dc.sourceScopus
dc.subjectCoronavirus
dc.subjectDisease control
dc.subjectSars coronavirus
dc.subjectVaccines/vaccine strains
dc.subjectVirus classification
dc.subjectAdult
dc.subjectAnaphylaxis
dc.subjectAnti-inflammatory agents
dc.subjectCovid-19
dc.subjectCovid-19 vaccines
dc.subjectEpinephrine
dc.subjectHumans
dc.subjectMale
dc.subjectRecurrence
dc.subjectSars-cov-2
dc.subjectTreatment outcome
dc.subjectVaccines, synthetic
dc.subjectAmoxicillin plus clavulanic acid
dc.subjectDexamethasone
dc.subjectDiphenhydramine
dc.subjectHouse dust allergen
dc.subjectHydrocortisone
dc.subjectHydrocortisone sodium succinate
dc.subjectParacetamol
dc.subjectPethidine
dc.subjectPrednisone
dc.subjectRna vaccine
dc.subjectSars-cov-2 vaccine
dc.subjectAntiinflammatory agent
dc.subjectBnt 162 vaccine
dc.subjectRecombinant vaccine
dc.subjectArticle
dc.subjectArytenoid cartilage
dc.subjectCase report
dc.subjectChill
dc.subjectClinical article
dc.subjectCoronavirus disease 2019
dc.subjectDiaphoresis
dc.subjectDisease association
dc.subjectDisease severity
dc.subjectDrug exposure
dc.subjectDrug hypersensitivity
dc.subjectDysphagia
dc.subjectDyspnea
dc.subjectEmergency ward
dc.subjectErythema
dc.subjectEyelid disease
dc.subjectFlexible fiberoptic laryngoscopy
dc.subjectHome
dc.subjectHouse dust allergy
dc.subjectHuman
dc.subjectInfection control
dc.subjectLip swelling
dc.subjectMaculopapular rash
dc.subjectNose cavity
dc.subjectNose edema
dc.subjectOtorhinolaryngology
dc.subjectPatient assessment
dc.subjectPollen allergy
dc.subjectPruritus
dc.subjectRegistered nurse
dc.subjectSevere acute respiratory syndrome coronavirus 2
dc.subjectSymptom
dc.subjectTachycardia
dc.subjectTachypnea
dc.subjectTongue edema
dc.subjectUrticaria
dc.subjectVaccination
dc.subjectAdverse event
dc.subjectImmunology
dc.subjectPrevention and control
dc.subjectRecurrent disease
dc.titleBiphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-5847.pdf
Size:
335.19 KB
Format:
Adobe Portable Document Format
Download

Collections

Otolaryngology/Head and Neck Surgery